Profile data is unavailable for this security.
About the company
CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL CO.,LTD. is a China-based company principally engaged in the development, manufacture and distribution of pharmaceuticals. The Company's main businesses are classified into three segments: Chronic Disease segment, Specialist segment and Infusion segment. Chronic Disease segment mainly provides products for lowering blood pressure, blood fat and blood glucose. Specialist segment mainly involves in the research, development and distribution of pharmaceuticals targeting six areas, including cardiovascular and cerebrovascular, pediatrics, kidney disease, mental/nerve, anesthesia and analgesia and respiratory areas. Infusion segment various types of infusion products, such as basic infusion, therapeutic infusion and nutritional. The Company distributes its products mainly in domestic market.
- Revenue in CNY (TTM)10.32bn
- Net income in CNY1.38bn
- Incorporated1997
- Employees12.27k
- LocationChina Resources Double-Crane Pharmaceutical Co LtdNo.1 Lize East Er RoadWangjing, Chaoyang DistrictBEIJING 100102ChinaCHN
- Phone+86 1 064398099
- Fax+86 1 064398086
- Websitehttps://www.dcpc.com/
More ▼
Mergers & acquisitions
| Acquired company | 600062:SHH since announced | Transaction value |
|---|---|---|
| China Resources Zizhu Pharmaceutical Co Ltd | 9.86% | 433.04m |
| Guizhou Tianan Pharmaceutical Co Ltd | 24.20% | 35.61m |
Data delayed at least 15 minutes, as of May 28 2024 08:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sinocelltech Group Ltd | 2.17bn | -168.81m | 19.81bn | 2.33k | -- | -- | -- | 9.12 | -0.3791 | -0.3791 | 4.88 | -1.16 | 0.761 | 0.3743 | 6.86 | 930,592.90 | -5.93 | -40.17 | -15.48 | -74.63 | 96.35 | 95.42 | -7.79 | -108.20 | 0.4649 | 3.33 | 1.23 | -- | 84.46 | 264.19 | 23.70 | -- | 37.54 | -- |
| Chongqing Taiji Industry Group Co Ltd | 15.40bn | 834.00m | 21.04bn | 12.59k | 25.23 | 5.44 | -- | 1.37 | 1.50 | 1.50 | 27.66 | 6.95 | 1.03 | 3.15 | 5.84 | 1,223,535.00 | 5.77 | 0.7814 | 17.83 | 2.35 | 46.14 | 44.03 | 5.62 | 0.8498 | 0.5315 | 6.12 | 0.5393 | 25.76 | 10.58 | 7.88 | 131.99 | 63.55 | 3.86 | 24.57 |
| Tasly Pharmaceutical Group Co Ltd | 8.64bn | 1.10bn | 21.41bn | 9.22k | 19.52 | 1.69 | -- | 2.48 | 0.7342 | 0.7342 | 5.77 | 8.47 | 0.4899 | 1.72 | 10.80 | 937,046.80 | 5.93 | 5.47 | 7.21 | 7.25 | 65.67 | 48.42 | 12.11 | 8.94 | 2.73 | 5.91 | 0.2083 | 50.99 | 0.4236 | -13.57 | 505.34 | -7.07 | -3.03 | 1.92 |
| Nanjing King-Frind Bchmcl Phrmctcl C Ltd | 3.63bn | -344.58m | 21.79bn | 1.45k | -- | 3.63 | -- | 6.01 | -0.2727 | -0.2727 | 2.30 | 3.71 | 0.3561 | 0.4354 | 3.35 | 2,500,466.00 | -3.38 | 8.97 | -4.83 | 13.15 | 43.57 | 45.59 | -9.50 | 20.12 | 1.15 | -- | 0.3129 | 26.33 | 5.89 | 18.25 | -117.37 | -- | 38.32 | 13.75 |
| Xiamen Amoytop Biotech Co Ltd | 2.23bn | 600.08m | 22.57bn | 1.96k | 37.61 | 11.26 | -- | 10.14 | 1.48 | 1.48 | 5.47 | 4.93 | 1.04 | 0.8541 | 6.70 | 1,135,877.00 | 28.09 | 17.96 | 32.72 | 21.02 | 93.17 | 90.48 | 26.95 | 19.17 | 3.22 | -- | 0.0037 | 26.95 | 37.55 | 36.19 | 93.52 | 103.28 | 81.61 | -- |
| China Resources Dubl-Crne Phrmctl Co Ltd | 10.32bn | 1.38bn | 22.79bn | 12.27k | 16.34 | 1.95 | -- | 2.21 | 1.34 | 1.34 | 10.07 | 11.24 | 0.6781 | 2.85 | 5.82 | 841,054.60 | 8.87 | 8.58 | 11.67 | 11.21 | 54.25 | 58.19 | 13.08 | 11.98 | 2.15 | -- | 0.0249 | 35.91 | 6.20 | 4.44 | 12.96 | 6.60 | 21.46 | -1.63 |
| Shanghai Junshi Biosciences Co Ltd | 1.63bn | -2.02bn | 23.55bn | 2.57k | -- | 3.96 | -- | 14.46 | -2.06 | -2.06 | 1.66 | 6.97 | 0.1348 | 1.05 | 4.11 | 634,034.10 | -18.18 | -18.87 | -23.17 | -23.11 | 64.05 | 69.13 | -134.86 | -88.41 | 1.91 | -215.80 | 0.3018 | -- | 3.38 | 248.39 | 4.38 | -- | 8.36 | -- |
| Joincare Pharmaceutical Group Ind. Co. | 16.43bn | 1.42bn | 23.72bn | 14.37k | 16.56 | 1.67 | -- | 1.44 | 0.7676 | 0.7676 | 8.86 | 7.63 | 0.4522 | 2.36 | 5.57 | 1,143,551.00 | 7.98 | 8.46 | 16.51 | 18.84 | 61.23 | 62.72 | 17.64 | 17.00 | 2.11 | -- | 0.2247 | 28.86 | -2.90 | 8.24 | -3.99 | 15.58 | 11.53 | 2.38 |
| Shanghai Allist Pharmaceuticals Co Ltd | 2.48bn | 915.35m | 25.73bn | 1.04k | 28.11 | 5.95 | -- | 10.35 | 2.03 | 2.03 | 5.52 | 9.60 | 0.6091 | 3.16 | 10.51 | 2,379,802.00 | 22.44 | 0.6405 | 24.19 | 0.6933 | 94.48 | 96.42 | 36.84 | 2.54 | 8.22 | -- | 0.0004 | 211.88 | 155.14 | 237.34 | 393.54 | -- | 13.53 | -- |
| Zhejiang Huahai Pharmaceutical Co., Ltd. | 8.75bn | 928.37m | 25.97bn | 8.22k | 27.42 | 3.04 | -- | 2.97 | 0.6391 | 0.6391 | 6.02 | 5.76 | 0.4511 | 1.08 | 3.46 | 1,064,162.00 | 4.76 | 5.67 | 6.90 | 8.07 | 59.44 | 60.52 | 10.55 | 11.61 | 0.8451 | 5.48 | 0.5047 | 33.55 | 0.5199 | 10.28 | -28.88 | 50.51 | 7.21 | -- |
Data as of May 28 2024. Currency figures normalised to China Resources Double-Crane Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
6.77%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| E Fund Management Co., Ltd.as of 31 Dec 2023 | 25.54m | 2.49% |
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 8.88m | 0.87% |
| ICBC Credit Suisse Asset Management Co., Ltd.as of 31 Dec 2023 | 8.24m | 0.81% |
| CITIC Securities Co., Ltd. (Invt Port)as of 30 Sep 2023 | 5.79m | 0.57% |
| Guotai Asset Management Co., Ltd.as of 31 Dec 2023 | 4.17m | 0.41% |
| Cinda Fund Management Co. Ltd.as of 31 Dec 2023 | 3.78m | 0.37% |
| China Merchants Fund Management Co., Ltd.as of 31 Dec 2023 | 3.59m | 0.35% |
| HuaAn Fund Management Co., Ltd.as of 31 Dec 2023 | 3.44m | 0.34% |
| China Southern Asset Management Co., Ltd.as of 31 Dec 2023 | 3.12m | 0.31% |
| China Asset Management Co., Ltd.as of 31 Dec 2023 | 2.75m | 0.27% |
More ▼
Data from 31 Dec 2023 - 29 Apr 2024Source: FactSet Research Systems Inc.
